245 related articles for article (PubMed ID: 36934113)
1. The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma.
Lim SY; Shklovskaya E; Lee JH; Pedersen B; Stewart A; Ming Z; Irvine M; Shivalingam B; Saw RPM; Menzies AM; Carlino MS; Scolyer RA; Long GV; Rizos H
Nat Commun; 2023 Mar; 14(1):1516. PubMed ID: 36934113
[TBL] [Abstract][Full Text] [Related]
2. Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma.
Anagnostou V; Bruhm DC; Niknafs N; White JR; Shao XM; Sidhom JW; Stein J; Tsai HL; Wang H; Belcaid Z; Murray J; Balan A; Ferreira L; Ross-Macdonald P; Wind-Rotolo M; Baras AS; Taube J; Karchin R; Scharpf RB; Grasso C; Ribas A; Pardoll DM; Topalian SL; Velculescu VE
Cell Rep Med; 2020 Nov; 1(8):100139. PubMed ID: 33294860
[TBL] [Abstract][Full Text] [Related]
3. Comparing anti-tumor and anti-self immunity in a patient with melanoma receiving immune checkpoint blockade.
Chen S; McMiller TL; Soni A; Succaria F; Sidhom JW; Cappelli LC; Casciola-Rosen LA; Morales IR; Sankaran P; Berger AE; Deutsch JS; Zhu QC; Anders RA; Hooper JE; Pardoll DM; Lipson EJ; Taube JM; Topalian SL
J Transl Med; 2024 Mar; 22(1):241. PubMed ID: 38443917
[TBL] [Abstract][Full Text] [Related]
4. The role of interferons in melanoma resistance to immune checkpoint blockade: mechanisms of escape and therapeutic implications.
Hargadon KM
Br J Dermatol; 2021 Dec; 185(6):1095-1104. PubMed ID: 34185875
[TBL] [Abstract][Full Text] [Related]
5. Multiparametric MRI of early tumor response to immune checkpoint blockade in metastatic melanoma.
Lau D; McLean MA; Priest AN; Gill AB; Scott F; Patterson I; Carmo B; Riemer F; Kaggie JD; Frary A; Milne D; Booth C; Lewis A; Sulikowski M; Brown L; Lapointe JM; Aloj L; Graves MJ; Brindle KM; Corrie PG; Gallagher FA
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34561275
[TBL] [Abstract][Full Text] [Related]
6. G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma.
Kelly GM; Al-Ejeh F; McCuaig R; Casciello F; Ahmad Kamal N; Ferguson B; Pritchard AL; Ali S; Silva IP; Wilmott JS; Long GV; Scolyer RA; Rao S; Hayward NK; Gannon F; Lee JS
Clin Cancer Res; 2021 May; 27(9):2624-2635. PubMed ID: 33589432
[TBL] [Abstract][Full Text] [Related]
7. Advanced Melanoma: Resistance Mechanisms to Current Therapies.
Haugh AM; Salama AKS; Johnson DB
Hematol Oncol Clin North Am; 2021 Feb; 35(1):111-128. PubMed ID: 33759769
[TBL] [Abstract][Full Text] [Related]
8. Innate immune checkpoint inhibitor resistance is associated with melanoma sub-types exhibiting invasive and de-differentiated gene expression signatures.
Hossain SM; Gimenez G; Stockwell PA; Tsai P; Print CG; Rys J; Cybulska-Stopa B; Ratajska M; Harazin-Lechowska A; Almomani S; Jackson C; Chatterjee A; Eccles MR
Front Immunol; 2022; 13():955063. PubMed ID: 36248850
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients.
Pirozyan MR; McGuire HM; Emran AA; Tseng HY; Tiffen JC; Lee JH; Carlino MS; Menzies AM; Long GV; Scolyer RA; Fazekas de St Groth B; Hersey P
Front Immunol; 2020; 11():372. PubMed ID: 32210968
[TBL] [Abstract][Full Text] [Related]
10. Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma.
Zhang W; Kong Y; Li Y; Shi F; Lyu J; Sheng C; Wang S; Wang Q
Front Immunol; 2021; 12():798474. PubMed ID: 35087523
[TBL] [Abstract][Full Text] [Related]
11. A20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma.
Guo W; Ma J; Guo S; Wang H; Wang S; Shi Q; Liu L; Zhao T; Yang F; Chen S; Chen J; Zhao J; Yu C; Yi X; Yang Y; Ma J; Ni Q; Zhu G; Gao T; Li C
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33298620
[TBL] [Abstract][Full Text] [Related]
12. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic control of
Wang MM; Koskela SA; Mehmood A; Langguth M; Maranou E; Figueiredo CR
Front Immunol; 2023; 14():1152228. PubMed ID: 37077920
[TBL] [Abstract][Full Text] [Related]
14. Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma.
Trujillo JA; Luke JJ; Zha Y; Segal JP; Ritterhouse LL; Spranger S; Matijevich K; Gajewski TF
J Immunother Cancer; 2019 Nov; 7(1):295. PubMed ID: 31703593
[TBL] [Abstract][Full Text] [Related]
15. Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors.
Olbryt M; Rajczykowski M; Widłak W
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32517213
[TBL] [Abstract][Full Text] [Related]
16. Clonal dynamics of circulating tumor DNA during immune checkpoint blockade therapy for melanoma.
Takai E; Omata W; Totoki Y; Nakamura H; Shiba S; Takahashi A; Namikawa K; Mori T; Yamazaki N; Shibata T; Yachida S
Cancer Sci; 2021 Nov; 112(11):4748-4757. PubMed ID: 34477284
[TBL] [Abstract][Full Text] [Related]
17. Determinants of Resistance to Checkpoint Inhibitors.
Tran L; Theodorescu D
Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32111080
[TBL] [Abstract][Full Text] [Related]
18. Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma.
Lelliott EJ; McArthur GA; Oliaro J; Sheppard KE
Front Immunol; 2021; 12():661737. PubMed ID: 34025662
[TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Inhibitors and RAS-ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma.
Morante M; Pandiella A; Crespo P; Herrero A
Biomolecules; 2022 Oct; 12(11):. PubMed ID: 36358912
[TBL] [Abstract][Full Text] [Related]
20.
Ibáñez-Molero S; van Vliet A; Pozniak J; Hummelink K; Terry AM; Monkhorst K; Sanders J; Hofland I; Landeloos E; Van Herck Y; Bechter O; Kuilman T; Zhong W; Marine JC; Wessels L; Peeper DS
Oncoimmunology; 2022; 11(1):2139074. PubMed ID: 36465485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]